2014 Hepatology referees (volumes 59 and 60)
24 November 2014
24 November 2014
Christina Dorman, Mark Wong, Aazib Khan – 22 November 2014
Gwilym J. Webb, David H. Adams – 22 November 2014
John Y.L. Chiang – 22 November 2014
Changhua Ji, Yang Liu, Chandra Pamulapati, Sandhya Bohini, Georg Fertig, Michael Schraeml, Werner Rubas, Michael Brandt, Stefan Ries, Han Ma, Klaus Klumpp – 22 November 2014 – CD81 is a required receptor for hepatitis C virus (HCV) infection of human hepatocytes in vitro. We generated several high‐affinity anti‐human CD81 monoclonal antibodies (mAbs) that demonstrated potent, specific, and cross‐genotype inhibition of HCV entry.
Adrian M. Bisceglie, Anna S. Lok, Paul Martin, Norah Terrault, Robert P. Perrillo, Jay H. Hoofnagle – 21 November 2014 – Reactivation of hepatitis B in the context of immunosuppressive therapy may be severe and potentially fatal. The US Food and Drug Administration has recently drawn attention to the potentially fatal risk of hepatitis B reactivation in patients receiving the anti‐CD20 agents ofatumumab or rituximab.
Gian Ludovico Rapaccini – 21 November 2014
Stephen N. Greenhalgh, Kylie P. Conroy, Neil C. Henderson – 21 November 2014 – Rapid evolution in transgenic (Tg) mouse technology now permits cell‐specific and temporal control of fluorescent cell‐labeling and gene inactivation. Here, we discuss the principal strategies that have been utilized to target, label, and manipulate hepatic nonparenchymal cells, with emphasis on the utility of constitutive and inducible Cre‐lox systems.
Romina Salpini, Luna Colagrossi, Maria Concetta Bellocchi, Matteo Surdo, Christina Becker, Claudia Alteri, Marianna Aragri, Alessandra Ricciardi, Daniele Armenia, Michela Pollicita, Fabiola Di Santo, Luca Carioti, Yoram Louzoun, Claudio Maria Mastroianni, Miriam Lichtner, Maurizio Paoloni, Mariarosaria Esposito, Chiara D'Amore, Aldo Marrone, Massimo Marignani, Cesare Sarrecchia, Loredana Sarmati, Massimo Andreoni, Mario Angelico, Jens Verheyen, Carlo‐Federico Perno, Valentina Svicher – 21 November 2014 – Hepatitis B virus (HBV) reactivation during immunosuppression can lead to severe acute
Hans L. Zaaijer – 21 November 2014